Migraine Prevention Research
Explore migraine prevention research, including preventive treatments, clinical trials, Botox and treatment strategies.
-
Safety and Efficacy of Atogepant for Migraine Prevention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Authors: Akram Nizamani S, Memon R, Iguh C, Ali R, Omomhenle OD Systematic review / meta-analysis
Migraine is a common neurological disorder that can severely affect daily life. Atogepant is a new oral medication designed to prevent migraines. This study reviewed six high-quality trials involving 3,453 patients…
-
Fremanezumab for the preventive treatment of migraine in Chinese adults: A Phase 3, randomized controlled trial with an open-label extension.
Authors: Yu S, Su H, Wang H, Zhang M, Barash S Clinical trial
Fremanezumab is a treatment approved for migraine prevention in many countries. This study focused on its effects in Chinese adults with migraines. Researchers conducted a Phase 3 trial with three groups. One group…
-
Lamotrigine prophylaxis is associated with reduced aura frequency in patients with burdensome migraine aura: a retrospective observational study.
Authors: Uzun S, Frejvall U, Karatas H, Petersson P, Sahin G Observational study
Migraine aura affects about one-third of migraine sufferers. For some, this condition is very disabling. Effective treatments are often lacking for these patients. This study looked at lamotrigine (LTG) as a…
-
Flunarizine and cinnarizine in the prophylaxis of vestibular migraine and migraine-associated menière's disease: An 8-month retrospective study.
Authors: di Santillo LS, Califano L Observational study
This study looked at two treatments for vestibular migraine (VM) and migraine-associated Menière's disease (MAMD). These conditions cause frequent vertigo and can severely affect quality of life. Researchers analyzed…
-
[Pituitary adenylate-cyclase activating polypeptide (PACAP)-targeting treatment as a potential migraine prophylactic therapy].
Authors: Tajti J, Csáti A, Körtési T, Vécsei L, Szok D Review
In migraine prevention, new treatments are being explored that target PACAP. Current options include monoclonal antibodies (mAbs) and other specific drugs. Researchers conducted a review of existing literature on…
-
Association of Serum hs-CRP and TNF-α With Therapeutic Response to Erenumab for Migraine Prevention: A Registry for Migraine (REFORM) Study.
Authors: Karlsson WK, Christensen RH, Al-Khazali HM, Olsen DA, Madsen JS Observational study
This study explored the role of inflammatory markers in predicting migraine treatment success. Researchers focused on two markers: high-sensitivity C-reactive protein and tumor necrosis factor-alpha. They studied…
-
Chronic migraine management with onabotulinumtoxinA and anti-CGRP/R monoclonal antibodies in an Italian real-world setting: update on therapeutic appropriateness and an emerging role of pharmacy.
Authors: Scuteri D, Naturale MD, Pagliaro M, Brescia A, De Francesco AE Guideline / consensus
Migraine is a challenging neurovascular disorder that can progress to chronic forms. This progression may result in medication-overuse headache, leading to higher healthcare costs. The need for preventive treatments…
-
Real-world assessment of effectiveness and safety of candesartan in migraine prevention: Results of the French FHU InovPain registry.
Authors: Ferrao-Malheiro S, Fabre R, Lanteri-Minet M Observational study
Candesartan is recommended for migraine prevention, but real-world data is limited. This study analyzed adults starting candesartan in the French FHU InovPain registry. Patients were assessed at month 3, month 9, and…
-
Targeted liquid chromatography-tandem mass spectrometry profiling of arginine and histidine derivatives in chronic migraine: Discriminatory performance and changes after onabotulinumtoxinA therapy.
Authors: Dumur S, Diarra K, Sewidan J, Kalmoni JJ, Aygun D Observational study
This study explored the role of specific amino acids in chronic migraine patients. Researchers evaluated plasma levels of arginine, histidine, and their derivatives. They aimed to identify potential biomarkers for…
-
Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project).
Authors: Gago-Veiga AB, Lopez-Rodriguez AB, Sanchez Jimenez M, Iglesias Rubio A, Montes N Observational study
Rimegepant is a CGRP receptor antagonist for treating episodic migraines. This study examined rimegepant's effectiveness in patients with previous treatment failures. It was conducted across nine headache units in…
-
Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series.
Authors: Shah T, Dougherty C, Ailani J, Kerrigan T Case report / case series
Obesity often worsens migraine symptoms and increases their frequency and severity. Recent studies indicate that GLP-1 receptor agonists may help in pain modulation. Researchers observed two patients with migraine…
-
Cerebrovascular risk with calcitonin gene-related peptide monoclonal antibodies versus onabotulinumtoxinA in patients with migraine: A real-world pharmacoepidemiologic study in the National Institutes of Health All of Us Research Program.
Authors: Gül S, Ong B, Trudeau S, Thompson N, Yuan H Observational study
In a study comparing treatments for migraine, researchers evaluated calcitonin gene-related peptide monoclonal antibodies, or CGRP mAbs, and onabotulinumtoxinA. They aimed to determine if CGRP mAbs were non-inferior…
-
Fremanezumab for the Preventive Treatment of Chronic Migraine
Authors: Silberstein et al. Clinical trial
Fremanezumab is a monoclonal antibody aimed at preventing chronic migraines. This study compared its effectiveness to placebo in a phase 3 trial. Patients with chronic migraines received one of three treatments. They…
MigraineMind Top 100 · #26 -
Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial
Authors: Tepper et al. Clinical trial
The study explored erenumab's safety and efficacy in chronic migraine patients. Researchers conducted a phase 2, randomized, double-blind trial across 69 centers in North America and Europe. Participants were adults…
MigraineMind Top 100 · #32 -
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
Authors: Silberstein et al. Guideline / consensus
This research provides updated recommendations for preventing migraine headaches. The authors aimed to identify effective pharmacologic therapies for migraine prevention. They analyzed studies published from June…
MigraineMind Top 100 · #35 -
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
Authors: Aurora et al. Clinical trial
This study investigates the effectiveness of onabotulinumtoxinA for chronic migraine treatment. It is part of the PREEMPT 1 trial, focused on safety and efficacy. The study lasted 24 weeks and included a…
MigraineMind Top 100 · #22 -
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program
Authors: Dodick et al. Clinical trial
This research investigates onabotulinumtoxinA, commonly known as BOTOX, for chronic migraine treatment. Chronic migraine is a common, debilitating condition that often remains untreated. The study pooled results from…
MigraineMind Top 100 · #29 -
Migraine prevalence, disease burden, and the need for preventive therapy
Authors: Lipton et al. Review
Migraine is a common issue affecting many people in the United States. This study aimed to reassess migraine prevalence and treatment patterns among the population. Researchers mailed a validated headache…
MigraineMind Top 100 · #1 -
Suppression of cortical spreading depression in migraine prophylaxis
Authors: Ayata et al. Review
Topiramate, valproate, propranolol, amitriptyline, and methysergide are commonly used for migraine prevention. However, their exact action mechanisms remain uncertain. Cortical spreading depression (CSD) is linked to…
MigraineMind Top 100 · #86 -
Topiramate for Migraine Prevention<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Authors: Brandes Clinical trial
Topiramate is an antiepileptic drug that may help prevent migraines. A large study tested topiramate's efficacy and safety in preventing migraines. The study included 483 patients aged 12 to 65 years. These patients…
MigraineMind Top 100 · #76